- Home
- ORIC
as 07-26-2024 4:00pm EST
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 726.8M | IPO Year: | 2020 |
| Target Price: | $20.29 | AVG Volume (30 days): | 774.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.27 - $16.65 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Oric Pharmaceuticals Inc. (ORIC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Mar 6 '24 | Sell | $16.21 | 40,000 | $648,380.00 | 728,544 | SEC Form 4 |
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Feb 6 '24 | Sell | $12.12 | 13,958 | $169,159.79 | 794,586 | SEC Form 4 |
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Feb 6 '24 | Sell | $12.30 | 26,042 | $320,186.39 | 768,544 | SEC Form 4 |
| Chacko Jacob | ORIC | President and CEO | Dec 15 '23 | Sell | $8.58 | 14,539 | $124,812.95 | 808,544 | SEC Form 4 |
| Piscitelli Dominic | ORIC | Chief Financial Officer | Dec 15 '23 | Sell | $8.58 | 5,282 | $45,338.05 | 83,809 | SEC Form 4 |
Latest Oric Pharmaceuticals Inc. News
ORIC Breaking Stock News: Dive into ORIC Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
GlobeNewswire
10 days ago
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
GlobeNewswire
18 days ago
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
Insider Monkey
18 days ago
Why Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts?
GlobeNewswire
21 days ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Simply Wall St.
3 months ago
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Compare ORIC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ORIC Oric Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.